How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Sell
40
DXR Quote, Financials, Valuation and Earnings
Last price:
$7.80
Seasonality move
:
8.79%
Day range:
$7.35 - $7.80
52-week range:
$6.55 - $10.00
Dividend yield:
0%
P/E ratio:
25.61x
P/S ratio:
17.87x
P/B ratio:
1.08x
Volume:
3.3K
Avg. volume:
7.4K
1-year change:
-20.33%
Market cap:
$38.5M
Revenue:
$2.1M
EPS (TTM):
-$0.09
Analysts' Opinion
-
Consensus RatingDaxor has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.50, Daxor has an estimated upside of 201.28% from its current price of $7.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing 100% downside risk from its current price of $7.80.
Fair Value
-
According to the consensus of 1 analyst, Daxor has 201.28% upside to fair value with a price target of $23.50 per share.
DXR vs. S&P 500
-
Over the past 5 trading days, Daxor has underperformed the S&P 500 by -1.98% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Daxor does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Daxor has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Daxor reported revenues of --.
Earnings Growth
-
Daxor has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Daxor reported earnings per share of --.
Enterprise value:
39.2M
EV / Invested capital:
--
Price / LTM sales:
17.87x
EV / EBIT:
--
EV / Revenue:
18.40x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
1.52%
Net Income Margin (TTM):
25.17%
Return On Equity:
1.57%
Return On Invested Capital:
1.52%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $335.2K | $342.6K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | $0.53 | -$0.35 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.3K | $30.7K | $17.2K | $14.2K | $9.7K | |
| Total Assets | $16.6M | $25M | $30.3M | $34.9M | $36.6M | |
| Current Liabilities | $80K | $87.4K | $62.4K | $103.1K | $110.3K | |
| Total Liabilities | $877.7K | $3.8M | $1.3M | $858.8K | $840.3K | |
| Total Equity | $15.7M | $21.2M | $29M | $34M | $35.8M | |
| Total Debt | $170.7K | $3M | $1.2M | $755.7K | $730K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2009-12-31 | 2010-12-31 | 2011-12-31 | 2010-12-31 | 2011-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$1.8M | -$989.9K | |
| Cash From Investing | -- | -- | -- | $6.5M | -$8.1M | |
| Cash From Financing | -- | -- | -- | -$4.7M | $9.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
DXR
Sector
Market Cap
$38.5M
$34.2M
Price % of 52-Week High
78%
42.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-20.33%
-41.76%
Beta (5-Year)
-0.059
0.737
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.75
200-day SMA
Sell
Level
$8.50
Bollinger Bands (100)
Sell
Level
7.47 - 8.65
Chaikin Money Flow
Sell
Level
-59.3K
20-day SMA
Sell
Level
$7.82
Relative Strength Index (RSI14)
Sell
Level
49.96
ADX Line
Buy
Level
16.48
Williams %R
Neutral
Level
-44.1479
50-day SMA
Buy
Level
$7.73
MACD (12, 26)
Buy
Level
1.11
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (28.1837)
Buy
CA Score
(Annual)
Level (1.8224)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-1.4526)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Stock Forecast FAQ
In the current month, DXR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DXR average analyst price target in the past 3 months is $23.50.
-
Where Will Daxor Stock Be In 1 Year?
According to analysts, the consensus estimate is that Daxor share price will rise to $23.50 per share over the next 12 months.
-
What Do Analysts Say About Daxor?
Analysts are divided on their view about Daxor share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Daxor is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is Daxor's Price Target?
The price target for Daxor over the next 1-year time period is forecast to be $23.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DXR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Daxor is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of DXR?
You can purchase shares of Daxor via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Daxor shares.
-
What Is The Daxor Share Price Today?
Daxor was last trading at $7.80 per share. This represents the most recent stock quote for Daxor. Yesterday, Daxor closed at $7.80 per share.
-
How To Buy Daxor Stock Online?
In order to purchase Daxor stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Rocket Lab Vs Intuitive Machines Stock
The commercialization of outer space is now in full swing,…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 13.86% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is up 13.26% over the past day.
Sell
38
NOC alert for Apr 23
Northrop Grumman [NOC] is down 12.3% over the past day.
